Results 101 to 110 of about 178,517 (322)

Bruton’s Tyrosine Kinase Inhibitors: A New Generation of Promising Agents for Multiple Sclerosis Therapy

open access: yesCells, 2021
B cells play a central role in the pathogenesis of multiple sclerosis (MS), as demonstrated through the success of various B cell-depleting monoclonal antibodies.
A. García‐Merino
semanticscholar   +1 more source

Characterization of the effects of BTK inhibition and monocyte-produced IL-8 on the hematopoietic stem cell niche [PDF]

open access: yes, 2020
Hematopoietic stem and progenitor cells (HSPCs) are multipotent stem cells that give rise to all blood cell lineages. During early zebrafish development, HSPCs interact closely with endothelial cells in an endothelial niche known as the Caudal ...
Belardo, Alexander
core  

Src Family Protein Tyrosine Kinases Induce Autoactivation of Bruton's Tyrosine Kinase [PDF]

open access: yesMolecular and Cellular Biology, 1995
Bruton's tyrosine kinase (Btk) is tyrosine phosphorylated and enzymatically activated following ligation of the B-cell antigen receptor. These events are temporally regulated, and Btk activation follows that of various members of the Src family of protein tyrosine kinases, thus raising the possibility that Src kinases participate in the Btk activation ...
Sandra J. Saouaf   +5 more
openaire   +3 more sources

Expert Perspective: Diagnosis and Treatment of Castleman Disease

open access: yesArthritis &Rheumatology, Accepted Article.
Summary Castleman disease (CD) is a major diagnostic challenge for Rheumatologists. Unicentric CD (UCD) involves one enlarged lymph node region whereas multicentric CD (MCD) involves multiple enlarged lymph node regions. Both UCD and MCD may exhibit a wide range of symptoms that overlap with other immune‐mediated conditions.
Luke Y.C. Chen   +2 more
wiley   +1 more source

Pharmacology and safety of TAS5315, a Bruton tyrosine kinase inhibitor, in healthy volunteers: First‐in‐human, randomized, ascending‐dose studies

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim TAS5315 is a Bruton tyrosine kinase (Btk) inhibitor in development for autoimmune and allergic diseases, including rheumatoid arthritis (RA) and chronic spontaneous urticaria (CSU). Two clinical studies evaluated the pharmacology and safety of single and multiple oral doses of TAS5315.
Yuji Kumagai   +4 more
wiley   +1 more source

Bruton's tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury

open access: yesNature Communications, 2015
Inflammasome activation has been implicated in various inflammatory diseases including post-ischaemic inflammation after stroke. Inflammasomes mediate activation of caspase-1, which subsequently induces secretion of pro-inflammatory cytokines such as IL ...
Minako Ito   +6 more
semanticscholar   +1 more source

Inhibition of Bruton's TK regulates macrophage NF-kappa B and NLRP3 inflammasome activation in metabolic inflammation [PDF]

open access: yes, 2020
Background and Purpose: There are no medications currently available to treat metabolic inflammation. Bruton's tyrosine kinase (BTK) is highly expressed in monocytes and macrophages and regulates NF-\u3baB and NLRP3 inflammasome activity; both propagate ...
Aranda-Tavio, H   +13 more
core   +2 more sources

Combating cancer immunotherapy resistance: a nano‐medicine perspective

open access: yesCancer Communications, EarlyView.
Abstract Cancer immunotherapy offers renewed hope for treating this disease. However, cancer cells possess inherent mechanisms that enable them to circumvent each stage of the immune cycle, thereby evading anti‐cancer immunity and leading to resistance.
Xiangyi Kong   +10 more
wiley   +1 more source

Bruton's tyrosine kinase inhibition effectively protects against human IgE-mediated anaphylaxis.

open access: yesJournal of Clinical Investigation, 2020
No known therapies can prevent anaphylaxis. Bruton's tyrosine kinase (BTK) is an enzyme thought to be essential for high-affinity IgE receptor (FcεRI) signaling in human cells.
M. Dispenza   +5 more
semanticscholar   +1 more source

FcγRIIB1 Inhibition of BCR-Mediated Phosphoinositide Hydrolysis and Ca2+ Mobilization Is Integrated by CD19 Dephosphorylation [PDF]

open access: yes, 1997
The B cell receptor for immunoglobulin G, FcγRIIB1, is a potent transducer of signals that block antigen-induced B cell activation. Coligation of FcγRIIB1 with B lymphocyte antigen receptors (BCR) causes premature termination of phosphoinositide ...
Buhl, Anne Mette   +5 more
core   +1 more source

Home - About - Disclaimer - Privacy